Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 03: 203 - 207

DOI: https://doi.org/10.16139/j.1007-9610.2021.03.005

Experts forum

Drug therapy for esophageal and gastric fundus varices in liver cirrhosis

Expand

Received date: 2021-04-19

  Online published: 2022-08-03

Fold

Cite this article

HU Mingli, WANG Qixia, MA Xiong . Drug therapy for esophageal and gastric fundus varices in liver cirrhosis[J]. Journal of Surgery Concepts & Practice, 2021 , 26(03) : 203 -207 . DOI: 10.16139/j.1007-9610.2021.03.005

References

[1] Alqahtani SA, Jang S. Pathophysiology and management of variceal bleeding[J]. Drugs, 2021, 81(6):647-667.
[2] Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11):1680-1704.
[3] de Franchis R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3):743-752.
[4] 徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 实用肝脏病杂志, 2016, 19(5):641-656.
[5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2):406-460.
[6] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11):1634-1641.
[7] 杨连粤, 白雪莉. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(12):1241-1247.
[8] Zanetto A, Garcia-Tsao G. Management of acute variceal hemorrhage[J]. F1000Res, 2019, 8:F1000 Faculty Rev-966.
[9] Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review[J]. Aliment Pharmacol Ther, 2011, 34(5):509-518.
[10] Tandon P, Abraldes JG, Keough A, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics[J]. Clin Gastroenterol Hepatol, 2015, 13(6):1189-1196.e2.
[11] Ready JB, Robertson AD, Goff JS, et al. Assessment of the risk of bleeding from esophageal varices by conti-nuous monitoring of portal pressure[J]. Gastroenterology, 1991, 100(5 Pt 1):1403-1410.
[12] D′Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995, 22(1):332-354.
[13] Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin for acute esophageal variceal hemorrhage[J]. Aliment Pharmacol Ther, 2003, 17(1):53-64.
[14] Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension[J]. Aliment Pharmacol Ther, 2003, 18(4):375-386.
[15] Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds[J]. Aliment Pharmacol Ther, 2012, 35(11):1267-1278.
[16] Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage[J]. Hepatology, 2014, 60(3):954-963.
[17] Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: a new view of an old problem[J]. Clin Gastroenterol Hepatol, 2015, 13(12):2109-2117.
[18] Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4):1219-1231.
[19] Turco L, Villanueva C, La Mura V, et al. A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis[J]. J Hepatol, 2017, 66(1 Supplement):S103-S104.
[20] Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010, 52(3):1017-1022.
[21] Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Gastroenterology, 2014, 146(7):1680-1690.e1.
[22] Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices[J]. Aliment Pharmacol Ther, 2010, 32(7):859-871.
[23] Puente A, Hernández-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an upda-ted systematic review[J]. Liver Int, 2014, 34(6):823-833.
[24] Bunchorntavakul C, Reddy KR. Pharmacologic management of portal hypertension[J]. Clin Liver Dis, 2019, 23(4):713-736.
[25] Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J]. Gastroenterology, 2004, 126(3):749-755.
[26] Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analy-sis[J]. Clin Gastroenterol Hepatol, 2017, 15(10):1521-1530.e8.
[27] Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5):1160-1170.e3.
[28] Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70(5):982-994.
[29] Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):167-180.
[30] Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial[J]. Liver Int, 2013, 33(8):1148-1157.
[31] 徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10):1847-1863.
[32] Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28(3):450-455.
Options
Outlines

/

〈 〉